CSPC Innovation Pharmaceutical's (300765.SZ) clinical trial for antibody-drug conjugate SYS6041 has been approved.

CSPC Innovation Pharmaceutical (300765.SZ) announced that its holding subsidiary CSPC PHARMA Giant Stone Biopharmaceutical Co., Ltd. (referred to as "Giant Stone Biopharm") recently received the Drug Clinical Trial Approval Notice for the antibody-drug conjugate SYS6041 issued by the National Medical Products Administration, and will soon begin clinical trials. The announcement reveals that SYS6041 is a monoclonal antibody-drug conjugate that can bind to specific receptors on the surface of tumors, enter cells through endocytosis, and release toxins to kill tumor cells. The product is classified as a Category 1 biological product for therapeutic use, and the approved indication for this round is advanced solid tumors, expected to be used in the treatment of ovarian cancer, endometrial cancer, breast cancer, non-small cell lung cancer, etc.